ASAPIPRANT


Synonyms	Asapiprant S-555739
Status
Molecule Category	UNKNOWN
UNII	B2LW71CRGL


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ZMZNWNTZRWXTJU-UHFFFAOYSA-N
Smiles	CC(C)Oc1ccc(S(=O)(=O)N2CCN(c3ccc(-c4ncco4)c(OCC(=O)O)c3)CC2)cc1
InChI	InChI=1S/C24H27N3O7S/c1-17(2)34-19-4-6-20(7-5-19)35(30,31)27-12-10-26(11-13-27)18-3-8-21(24-25-9-14-32-24)22(15-18)33-16-23(28)29/h3-9,14-15,17H,10-13,16H2,1-2H3,(H,28,29)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H27N3O7S
Molecular Weight	501.56
AlogP	3.1
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	9.0
Polar Surface Area	122.41
Molecular species	ACID
Aromatic Rings	3.0
Heavy Atoms	35.0

Bioactivity

Mechanism of Action	Action	Reference
Prostanoid DP receptor antagonist	ANTAGONIST	PubMed


Protein: Prostanoid DP receptor Description: Prostaglandin D2 receptor Organism : Homo sapiens Q13258 ENSG00000168229

Assay Description	Organism	Bioactivity
Antagonist activity at PGD2 receptor in human platelets assessed as inhibition of PGD2-mediated cAMP accumulation preincubated for 5 mins followed by PGD2 addition measured after 2 mins by HTRF assay	Homo sapiens	520.0 nM
Displacement of [3H]-PGD2 from PGD2 receptor in human platelet membranes after 2 hrs by micro beta scintillation counting analysis	Homo sapiens	240.0 nM
Antiallergic activity in Brown Norway rat model of ovalbumin-induced asthma assessed as inhibition of airway hyperresponsiveness at 10 mg/kg, po qd for 3 consecutive days administered 1 hr prior to fourth exposure of antigen relative to control	Rattus norvegicus	111.0 %
Antiallergic activity in Brown Norway rat model of ovalbumin-induced asthma assessed as inhibition of infiltration of inflammatory cells in bronchoalveoli at 10 mg/kg, po qd for 3 consecutive days administered 1 hr prior to fourth exposure of antigen by hemocytometry based light microscopy relative to control	Rattus norvegicus	65.0 %
Antiallergic activity in Brown Norway rat model of ovalbumin-induced asthma assessed as inhibition of mucus secretion in airway lavage fluid at 10 mg/kg, po qd for 3 consecutive days administered 1 hr prior to fourth exposure of antigen by ELISA relative to control	Rattus norvegicus	92.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL3545043
FDA SRS	B2LW71CRGL
PubChem	59232326
SureChEMBL	SCHEMBL1106973

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).